Home > Publications Database > The E3 ligase parkin maintains mitochondrial integrity by increasing linear ubiquitination of NEMO. > print

001     136839
005     20240321220138.0
024 7 _ |a 10.1016/j.molcel.2013.01.036
|2 doi
024 7 _ |a pmid:23453807
|2 pmid
024 7 _ |a 1097-2765
|2 ISSN
024 7 _ |a 1097-4164
|2 ISSN
024 7 _ |a altmetric:1272997
|2 altmetric
037 _ _ |a DZNE-2020-03161
041 _ _ |a English
082 _ _ |a 610
100 1 _ |a Müller-Rischart, A. Kathrin
|0 P:(DE-2719)9000425
|b 0
245 _ _ |a The E3 ligase parkin maintains mitochondrial integrity by increasing linear ubiquitination of NEMO.
260 _ _ |a New York, NY
|c 2013
|b Elsevier
264 _ 1 |3 print
|2 Crossref
|b Elsevier BV
|c 2013-03-01
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1710770581_18976
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
520 _ _ |a Parkin, a RING-between-RING-type E3 ubiquitin ligase associated with Parkinson's disease, has a wide neuroprotective activity, preventing cell death in various stress paradigms. We identified a stress-protective pathway regulated by parkin that links NF-κB signaling and mitochondrial integrity via linear ubiquitination. Under cellular stress, parkin is recruited to the linear ubiquitin assembly complex and increases linear ubiquitination of NF-κB essential modulator (NEMO), which is essential for canonical NF-κB signaling. As a result, the mitochondrial guanosine triphosphatase OPA1 is transcriptionally upregulated via NF-κB-responsive promoter elements for maintenance of mitochondrial integrity and protection from stress-induced cell death. Parkin-induced stress protection is lost in the absence of either NEMO or OPA1, but not in cells defective for the mitophagy pathway. Notably, in parkin-deficient cells linear ubiquitination of NEMO, activation of NF-κB, and upregulation of OPA1 are significantly reduced in response to TNF-α stimulation, supporting the physiological relevance of parkin in regulating this antiapoptotic pathway.
536 _ _ |a 341 - Molecular Signaling (POF3-341)
|0 G:(DE-HGF)POF3-341
|c POF3-341
|f POF III
|x 0
536 _ _ |a 342 - Disease Mechanisms and Model Systems (POF3-342)
|0 G:(DE-HGF)POF3-342
|c POF3-342
|f POF III
|x 1
542 _ _ |i 2013-03-01
|2 Crossref
|u https://www.elsevier.com/tdm/userlicense/1.0/
542 _ _ |i 2014-03-26
|2 Crossref
|u https://www.elsevier.com/open-access/userlicense/1.0/
588 _ _ |a Dataset connected to CrossRef, PubMed,
650 _ 7 |a Intracellular Signaling Peptides and Proteins
|2 NLM Chemicals
650 _ 7 |a NEMO protein, mouse
|2 NLM Chemicals
650 _ 7 |a NF-kappa B
|2 NLM Chemicals
650 _ 7 |a Ubiquitin-Protein Ligases
|0 EC 2.3.2.27
|2 NLM Chemicals
650 _ 7 |a parkin protein
|0 EC 2.3.2.27
|2 NLM Chemicals
650 _ 2 |a Animals
|2 MeSH
650 _ 2 |a Apoptosis
|2 MeSH
650 _ 2 |a Fibroblasts: metabolism
|2 MeSH
650 _ 2 |a HEK293 Cells
|2 MeSH
650 _ 2 |a Humans
|2 MeSH
650 _ 2 |a Intracellular Signaling Peptides and Proteins: genetics
|2 MeSH
650 _ 2 |a Intracellular Signaling Peptides and Proteins: metabolism
|2 MeSH
650 _ 2 |a Mice
|2 MeSH
650 _ 2 |a Mice, Knockout
|2 MeSH
650 _ 2 |a Mitochondria: metabolism
|2 MeSH
650 _ 2 |a NF-kappa B: genetics
|2 MeSH
650 _ 2 |a NF-kappa B: metabolism
|2 MeSH
650 _ 2 |a Neurons: metabolism
|2 MeSH
650 _ 2 |a Parkinson Disease: genetics
|2 MeSH
650 _ 2 |a Parkinson Disease: metabolism
|2 MeSH
650 _ 2 |a Signal Transduction
|2 MeSH
650 _ 2 |a Transfection
|2 MeSH
650 _ 2 |a Ubiquitin-Protein Ligases: genetics
|2 MeSH
650 _ 2 |a Ubiquitin-Protein Ligases: metabolism
|2 MeSH
650 _ 2 |a Ubiquitination: genetics
|2 MeSH
700 1 _ |a Pilsl, Anna
|0 P:(DE-HGF)0
|b 1
700 1 _ |a Beaudette, Patrick
|0 P:(DE-HGF)0
|b 2
700 1 _ |a Patra, Maria
|0 P:(DE-HGF)0
|b 3
700 1 _ |a Hadian, Kamyar
|0 P:(DE-HGF)0
|b 4
700 1 _ |a Funke, Maria
|0 P:(DE-HGF)0
|b 5
700 1 _ |a Peis, Regina
|0 P:(DE-HGF)0
|b 6
700 1 _ |a Deinlein, Alexandra
|0 P:(DE-HGF)0
|b 7
700 1 _ |a Schweimer, Carolin
|0 P:(DE-HGF)0
|b 8
700 1 _ |a Kuhn, Peer-Hendrik
|0 P:(DE-2719)2810327
|b 9
700 1 _ |a Lichtenthaler, Stefan F
|0 P:(DE-2719)2181459
|b 10
700 1 _ |a Motori, Elisa
|0 P:(DE-HGF)0
|b 11
700 1 _ |a Hrelia, Silvana
|0 P:(DE-HGF)0
|b 12
700 1 _ |a Wurst, Wolfgang
|0 P:(DE-2719)2000028
|b 13
700 1 _ |a Trümbach, Dietrich
|0 P:(DE-HGF)0
|b 14
700 1 _ |a Langer, Thomas
|0 P:(DE-HGF)0
|b 15
700 1 _ |a Krappmann, Daniel
|0 P:(DE-HGF)0
|b 16
700 1 _ |a Dittmar, Gunnar
|0 P:(DE-HGF)0
|b 17
700 1 _ |a Tatzelt, Jörg
|0 P:(DE-2719)9000396
|b 18
700 1 _ |a Winklhofer, Konstanze F
|0 P:(DE-2719)9000369
|b 19
|e Last author
773 1 8 |a 10.1016/j.molcel.2013.01.036
|b : Elsevier BV, 2013-03-01
|n 5
|p 908-921
|3 journal-article
|2 Crossref
|t Molecular Cell
|v 49
|y 2013
|x 1097-2765
773 _ _ |a 10.1016/j.molcel.2013.01.036
|g Vol. 49, no. 5, p. 908 - 921
|0 PERI:(DE-600)2001948-8
|n 5
|q 49:5<908 - 921
|p 908-921
|t Molecular cell
|v 49
|y 2013
|x 1097-2765
856 4 _ |u https://pub.dzne.de/record/136839/files/DZNE-2020-03161_Restricted.pdf
856 4 _ |u https://pub.dzne.de/record/136839/files/DZNE-2020-03161_Restricted.pdf?subformat=pdfa
|x pdfa
909 C O |p VDB
|o oai:pub.dzne.de:136839
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 0
|6 P:(DE-2719)9000425
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 9
|6 P:(DE-2719)2810327
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 10
|6 P:(DE-2719)2181459
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 13
|6 P:(DE-2719)2000028
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 18
|6 P:(DE-2719)9000396
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 19
|6 P:(DE-2719)9000369
913 1 _ |a DE-HGF
|b Gesundheit
|l Erkrankungen des Nervensystems
|1 G:(DE-HGF)POF3-340
|0 G:(DE-HGF)POF3-341
|3 G:(DE-HGF)POF3
|2 G:(DE-HGF)POF3-300
|4 G:(DE-HGF)POF
|v Molecular Signaling
|x 0
913 1 _ |a DE-HGF
|b Gesundheit
|l Erkrankungen des Nervensystems
|1 G:(DE-HGF)POF3-340
|0 G:(DE-HGF)POF3-342
|3 G:(DE-HGF)POF3
|2 G:(DE-HGF)POF3-300
|4 G:(DE-HGF)POF
|v Disease Mechanisms and Model Systems
|x 1
914 1 _ |y 2013
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b MOL CELL : 2017
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0310
|2 StatID
|b NCBI Molecular Biology Database
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0600
|2 StatID
|b Ebsco Academic Search
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b ASC
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
915 _ _ |a WoS
|0 StatID:(DE-HGF)0110
|2 StatID
|b Science Citation Index
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
915 _ _ |a WoS
|0 StatID:(DE-HGF)0111
|2 StatID
|b Science Citation Index Expanded
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1030
|2 StatID
|b Current Contents - Life Sciences
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1050
|2 StatID
|b BIOSIS Previews
915 _ _ |a IF >= 10
|0 StatID:(DE-HGF)9910
|2 StatID
|b MOL CELL : 2017
920 1 _ |0 I:(DE-2719)1110006
|k AG Lichtenthaler
|l Neuroproteomics
|x 0
920 1 _ |0 I:(DE-2719)1140001
|k AG Wurst
|l Genome Engineering
|x 1
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a I:(DE-2719)1110006
980 _ _ |a I:(DE-2719)1140001
980 _ _ |a UNRESTRICTED

LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21